Mixed neuronal/glial neoplasms represent a minority of intracranial neoplasms, typically associated with a more favorable prognosis than the more common higher-grade glial neoplasms. We describe a young man with headache, confusion, and slurred speech who was found to have a ganglioglioma.
CASE REPORT
A 19-year-old man with a history of chronic migraine headaches beginning in his early teens experienced an acute sudden onset of severe headache without provocation. Until this point the patient's headaches lacked atypical symptoms and responded well to over-the-counter medication, and thus he had not undergone previous imaging evaluation. His family noticed that he was confused and had slurred speech, a marked change in the typical character of his headaches. Upon presentation to the emergency department, a noncontrast brain computed tomography (CT) scan (Figure 1 ) revealed a 6.9 × 3.2 cm isodense nonhemorrhagic mass centered in the left occipital lobe with scattered coarse calcifi c deposits, surrounding vasogenic edema, and local mass eff ect but no midline shift or hydrocephalus. Subsequent magnetic resonance imaging (MRI) of the brain further characterized the extent of the mass and revealed conspicuous cystic components (Figure 2a ). Mild heterogeneous enhancement was shown on the postgadolinium T1-weighted sequences (Figure 2b ). On the MRI, calcifi c deposits appeared as hypointense foci on the susceptibility weighted sequence ( Figure  2c ). Th e patient underwent a craniotomy and the mass was resected. Histologic examination revealed fi ndings compatible with a World Health Organization grade 1 ganglioglioma. Th e patient did well postoperatively without focal neurologic defi cit and will follow up for routine surveillance imaging.
DISCUSSION
Gangliogliomas are an uncommon lesion, accounting for 0.4% to 0.9% of all intracranial neoplasms and 1% to 4% of pediatric central nervous system neoplasms (1). Despite being uncommon, they are the most common mixed neuronal-glial neoplasm (2). Gangliogliomas have a peak incidence in patients 10 to 20 years old, with 80% being found in individuals younger than 30 years. In a case series of 99 proven gangliogliomas, 38% occurred in the temporal lobe, 30% in the parietal lobe, and 18% in the frontal lobe (3). Provenzale et al presented a series of 25 gangliogliomas, including two occipital lobe lesions (8%). Gangliogliomas are the most common neoplastic etiology (40%) for chronic temporal lobe epilepsy, particularly partial complex seizures (1) .
Th e imaging appearance of gangliogliomas is variable, with most presenting as mixed solid and cystic lesions (52%) (4, 5) . A superfi cial cortical site of involvement is most commonly encountered (2, 5, 6). On CT, these lesions are most commonly hypoattenuating (38%), followed by mixed density (32%) and hyperattenuating (15%) (4) . Calcifi c deposits most commonly occur in association with mixed solid/cystic masses and are seen in approximately 30% of gangliogliomas (2, 5) . Based on CT appearance alone, calcifi ed gangliogliomas may be indistinguishable from oligodendrogliomas.
Th e MRI appearance of gangliogliomas has classically been described as a cystic mass with an enhancing mural nodule (4, 5) . Th e presence of enhancement, however, is not indicative of a higher-grade neoplasm. Provenzale et al described a trend toward increasing tumor volume and prevalence of cystic components in those gangliogliomas occurring in early childhood (average age 5.5 years) compared with in young adulthood (average age 25.6 years) (6) .
Th e preferred treatment for gangliogliomas is complete surgical resection. Adjuvant chemotherapy and radiation are typically reserved for malignant lesions, with gangliogliomas demonstrating a rate of malignant transformation as high as 6%. Optimal technical surgical resections usually result in the complete resolution of seizure activity with only rare tumor recurrences (7) . Gangliogliomas and other mixed glioneuronal tumors may harbor BRAFV600E mutations, an area of potential targeted therapy with agents such as vemurafenib. 
